Survivin and Caspase-3 Cannot Predict Recurrence for Urinary Bladder Carcinoma

Bladder cancer is a major health problem. The limitations of poor sensitivity of cytology and the invasiveness of cystoscopy have generated interest in other non-invasive tools to monitor tumor recurrence. The measurement of survivin can aid the early diagnosis of bladder cancer, determine prognosis...

Full description

Saved in:

Bibliographic Details
Published in:	SN comprehensive clinical medicine Vol. 3; no. 11; pp. 2292 - 2300
Main Authors:	Rouston, Vivian G. D., Shaaban, Amal A. A., Abd Allah, Dina M., Kotb, Ahmed F.
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01-11-2021
Subjects:	Medicine Medicine & Public Health Original Paper Topical Collection on Surgery Bladder cancer; Apoptosis; Caspase-3; Survivin; TURBT
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Bladder cancer is a major health problem. The limitations of poor sensitivity of cytology and the invasiveness of cystoscopy have generated interest in other non-invasive tools to monitor tumor recurrence. The measurement of survivin can aid the early diagnosis of bladder cancer, determine prognosis, and predict treatment outcomes. Its combination with other biomarkers as caspase-3 in this study may enhance prognostication and prediction of treatment response in bladder cancer, as well as tumor recurrence. The present study included 51 prospective consecutive patients undergoing transurethral resection of a bladder tumor (TURBT) for suspected bladder cancer. Immunohistochemical (IHC) staining and scoring for survivin and caspase-3 were done and then correlated with available clinical parameters. Seven patients had no cancer diagnosis, and none of them had positive immunoreactivity. Forty-four patients had bladder cancer, and expression of survivin and caspase-3 was present in 42 (95.5%) and 10 (22.7%) cases, respectively. There was no statistically significant correlation between recurrence and either survivin or caspase-3 expression. Survivin and/ or caspase-3 is not recommended as a part of the workup for bladder cancer, as their clinical applicability is very doubtful.
ISSN:	2523-8973 2523-8973
DOI:	10.1007/s42399-021-01052-6